Organoids Market Expansion Fueled by Drug Discovery and 3D Cell Culture Innovations

Global organoids market size was estimated at about USD 1.6 billion in 2025 and is expected to reach around USD 1.9 billion in 2026, rising up to roughly USD 7.8 billion in 2035, growing at approximately 17.2% CAGR from 2026 to 2035.

The global organoids market is witnessing consistent growth primarily due to growing acceptance of advanced drug discovery technologies and disease modeling, cumulative demand for precision medicine, growing investments in regenerative medicine research, and increasing use of stem cell technologies. Pharmaceutical companies and researchers are using organoids more in 3D cell culture representations to ensure higher accuracy in preclinical testing and replicating human biological responses. Capital support from governments like the U.S. National Institutes of Health, the European Medicines Agency and Japan’s Ministry of Health, Labor and Welfare for research and innovation further promotes market growth.

Global Organoids Market Segmentation and Key Players

By Type, Liver Organoids Dominated the Global Organoids Market

Liver organoids contributed about 32% to the market in 2025 supported by their wide adoption and widespread use in preclinical studies, drug toxicity testing and liver disease research as they can meticulously mimic liver functions of humans.

North America Dominated the Global Organoids Market

North America accounted for nearly 41% of the market share in 2025 due to a robust biomedical research infrastructure, higher investments in pharmaceutical research and development and increasing government support for biotechnology and precision medicine discovery.

Some of the major players in this market are 3D BioMatrix Ltd., Agilent Technologies Inc., BGI Genomics Co. Ltd., Charles River Laboratories International Inc., Corning Incorporated, Crown Bioscience Inc., Danaher Corporation, Merck KGaA, Organovo Holdings Inc., and Thermo Fisher Scientific Inc.

Recent Developments by the Key Players

Merck KGaA upgraded its portfolio by including advanced organoid and cell culture reagents to strengthen its position in supporting translational biomedical research and drug discovery.

Charles River Laboratories International Inc. extended its services for preclinical research with higher focus on organoid-based testing platforms to improve predictive toxicology competences for biotechnology and pharmaceutical clients.